RECENT UPDATES IN MEDICINAL CHEMISTRY AND APPLIED MICROBIOLOGY





Dr. T. Gopalakrishnan Dr. M. Santhoshkumar Principal

Excel College for Commerce and Science

Komarapalavam - 637 303

Copyright ©2023 by ACTA Classic Publisher. All Rights Reserved



Published by

ACTA Classic Publisher

A.C.T Academy, Office: Suleeswaranpatti, Pollachi

Coimbatore- 642002

Cell:+916369453300

Email: act.academy2021@gmail.com

Published in India.

International Standard Book Number (ISBN): 978-81-966183-3-9

Price: Rs. 725/-

Publisher's Notice: This edited book (E-book) cannot be duplicated in any way—by photostat, microfilm, xerography, or any other method—or integrated into any kind of information retrieval system, mechanical or electronic, without the publisher's written consent. If you would like permission to photocopy or use any electronic material from this work, please send an email to the book editor or publisher.

Trademark Information: All product and brand names mentioned in this book are trademarks or registered trademarks of their respective owners and are protected by trademark, brand, or patent laws. The use of trade names, common names, product names, brand names, product descriptions, and other names in this work—even in the absence of a specific marking—does not in any way imply that these names are free to be used in any way that would violate trademark and brand protection laws. Additionally, books published by ACTA Classic Publisher are available in a range of electronic formats. It's possible that some print-only content isn't available in electronic formats.

This Book has been published in good faith that the material provided by author is original.

Every effort is made to ensure accuracy of material, but the publisher and printer will not be

held responsible for any inadvertent errors.

Principal

Cel College for Commerce and Science

Komarapalayam - 637 303

Edited Book Entitled

"Recent Updates in Medicinal Chemistry and Applied Microbiology"

INDEX

		CONTENTS
S.No	Title of the Chapters & Authors' Name	Pages
1	Comprehensive Insights into Mucormycosis	01-10
	Dr. D. Ramya	
2	Nanoparticles as therapeutic Biomaterials	11-22
	Dr. Aji Jovitha A T , Dr. Deivasigamani B	
3	Viral Hepatitis-B: Structure and Therapies	23-32
	Dr. Tanu Yadav, Dr. Suchit Swaroop	
4	Marine Quorum Sensing and Mechanism Dr. Rasheeda E.V, Hasna K P	33-50
5	Artificial Intelligence in Drug Discovery S. Salomie Jennifer	51-61
6	Food Borne Pathogens and its Pathophysiology Dr. R. Thenmozhi, R Dharini and Dr. Dharitri Borah	62-74
7	History and Formulation Development of Antibiotics <i>Prof. (Dr.) Niraj Gupta</i>	75-96
8	Synthetic Drug Designing Approach in Vaccine Production Technology Dr. D. Gayathri and Dr. V. Gokula	97- 102
9	Role of Microbial Symbionts in Agriculture	103-115
	Dr. A. Balamurugan	





COMPREHENSIVE INSIGHTS INTO MUCORMYCOSIS

Dr. D. Ramya*, Assistant Professor, Department of Microbiology

Excel College for Commerce and Science, Komarapalayam -637303, Tamil Nadu, India.

Corresponding author Email ID: ramya.susila@gmail.com

ABSTRACT

Mucormycosis, a rare but life-threatening fungal infection, has gained global attention due to its association with the COVID-19 pandemic. This study provides a comprehensive overview of mucormycosis, encompassing its epidemiology, risk factors, pathogenesis, diagnosis, and treatment. The objective is to enhance understanding and aid in the development of effective strategies for prevention and management. Epidemiological trends demonstrate an alarming rise in mucormycosis cases, particularly in individuals with COVID-19, diabetes, or immunocompromised conditions. The pathogenesis involves the invasion of tissues by Mucorales fungi, leading to devastating consequences. Early diagnosis is critical, involving a combination of clinical, radiological, and microbiological assessments. Timely intervention with antifungal therapy and surgical debridement is imperative for patient survival. The study concludes that increased awareness, risk factor mitigation, and healthcare system preparedness are essential in the battle against Mucormycosis.

Key words: Mucormycosis; COVID-19; Epidemiology; Pathogenesis; Diagnosis and Treatment.

INTRODUCTION

American pathologist R.D. Baker coined the term *Mucormycosis*, also recognized as *Zygomycosis*. This refers to a subtle fungal infection caused by members of *Mucorales* and *zygomycotic* species. Mucormycotina, common saprobes originating from decaying matter or soils, are implicated. Infections involving Mucorales are characterized by swift progression (Kwon-Chung, 2012). In 1885, the German pathologist Paltauf documented the first case of Mucormycosis, terming it Mycosis Mucorina (Mohammadi et al., 2014). According to a study in France, there was a 7.4% annual increase in occurrence of Mucormycosis (Bitar et al., 2009). The universal incidence and the potential for seasonal variation in mucorales infection have been acknowledged (Petrikkos et al., 2012). These potent and extremely damaging infections primarily manifest in individuals with compromised immune systems, particularly in those undergoing hematopoietic stem cell transplantation or individuals with haematological malignancies. Distinct risk groups include diabetic patients with ketoacidosis and individuals with transfusional/dyserythropoetic iron overload. Challenges in diagnosis and subsequent antifungal treatment, compounded by significant intrinsic resistance to commonly employed antifungal drugs, contribute to elevated mortality rates in specific patient populations (Binder et al., 2014).

Mucormycosis, caused by fungi of the order Mucorales, is primarily acquired by humans through the inhalation of sporangiospores, ingestion of contaminated food, or inoculation (Ribes et al., 2000 Richardson, 2009). The fungi belonging to Mucorales are widespread, exhibiting a

ISBN: 978-81-966183-3-9

=xcel College for Commerce and Science Komarapalayam - 637 303

Principal

